
Publikationsverzeichnis

Erst-/Letztautorenschaften

Lang SA*, Klein D*, Moser C, Gaumann A, Glockzin G, Dahlke MH, Dietmaier W, Bolder U, Schlitt HJ, Geissler EK, Stoeltzing O
Inhibition of heat-shock protein 90 impairs EGF- mediated signaling in gastric cancer cells and reduces tumor growth and vascularization *in vivo*
Mol Can Ther, 2007 Mar 1;6(3):1123-1132

Lang SA, Gaumann A, Koehl GE, Seidel U, Bataille F, Klein D, Ellis LM, Bolder U, Hofstaedter F, Geissler EK, Stoeltzing O
Mammalian Target of Rapamycin (mTOR) is activated in human gastric cancer serves as a target for therapy in an experimental model
Int J Cancer, 2007 Apr. 15;120(8):1803-1810

Lang SA, Moser C, Gaumann A, Klein D, Glockzin G, Popp FC, Dahlke MH, Piso P, Schlitt HJ, Geissler EK, Stoeltzing O
Targeting Hsp90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an IL-6/STAT3/HIF-1 α autocrine loop, and reduces orthotopic tumor growth
Clin Cancer Res 2007 Nov 1;13(21):6459-6468

Lang SA, Brecht I, Moser C, Obed A, Batt D, Schlitt HJ, Geissler EK, Stoeltzing O
Dual inhibition of B-Raf and VEGFR2 reduces growth and vascularization of hepatocellular carcinoma in an experimental model
Langenbecks Arch Surg, 2008; May; 393(3): 333-41

Moser C[#], **Lang SA[#]**, Mori A, Hellerbrand C, Schlitt HJ, Geissler EK, Fogler W, Stoeltzing O.
ENMD-1198, a novel tubulin-binding agent reduces HIF-1 and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization *in vivo*.
BMC Cancer. 2008 Jul 23;8(1):206.

Lang SA*, Schachtschneider P*, Moser C, Hackl C, Gaumann A, Batt D, Schlitt HJ, Geissler EK, Stoeltzing O
Targeting Raf and VEGF receptor-2 reduces growth of pancreatic cancer through direct effects on tumor cells, endothelial cells and pericytes.
Mol Cancer Ther. 2008 Nov;7(11):3509-18.

Lang SA, Moser C, Fichnter-Feigl S, Schachtschneider P, Hellerbrand C, Schmitz V, Schlitt HJ, Geissler EK, Stoeltzing O
Targeting heat-shock protein 90 (Hsp90) improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice
Hepatology, 2009, Feb;49(2):523-32

Lang SA, Glockzin G, Dahlke MH, Popp FC, Agha A, Schlitt HJ, Piso P
Technik der Peritonektomie sowie der hyperthermen intraperitonealen
Chemotherapie
Zentralbl Chir. 2009 Sep;134(5):443-9.

Lang SA, Hackl C, Moser C, Fichtner-Feigl S, Koehl G, Schlitt HJ, Geissler EK, Stoeltzing O
Implication of MTORC2/RICTOR in the MTOR inhibitor-mediated induction of insulin-like growth factor-I receptor (IGF-IR) and human epidermal growth factor receptor-2 (Her2) expression in gastrointestinal cancer cells
Biochim Biophys Acta. 2010 Apr;1803(4):435-42

Taeger J*, Moser C*, Hellerbrand C, Mycielska ME, Glockzin G, Schlitt HJ, Geissler EK, Stoeltzing O, **Lang SA**.
Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis and metastasis by effects on tumor cells, endothelial cells and pericytes in pancreatic cancer.
Mol Cancer Ther. 2011 Nov;10(11):2157-67. Epub 2011 Sep 1.

Schnitzbauer AA*, **Lang SA***, Goessmann H, Nadalin S, Baumgart J, Farkas SA, Fichtner-Feigl S, Lorf T, Goralcyk A, Hörbelt R, Kroemer A, Loss M, Ruemmele P, Geissler EK, Scherer NM, Padberg W, Königsrainer A, Lang H, Obed A, Schlitt HJ
Right Portal Vein Ligation Combined with In Situ Splitting Induces Rapid Left Lateral Liver Lobe Hypertrophy Enabling Two-Staged Extended Right Hepatic Resection in Small-for-Size Settings
Ann Surg. 2012 Mar;255(3):405-14.

Moser C, Ruemmele P, Gehmert S, Schenk H, Kreutz MP, Mycielska ME, Hackl C, Kroemer A, Schnitzbauer AA, Stoeltzing O, Schlitt HJ, Geissler EK, **Lang SA**
STAT5b as molecular target in pancreatic cancer – inhibition of tumor growth, angiogenesis and metastases
Neoplasia. 2012 Oct;14(10):915-25

Lang SA, Moser C, Gehmert S, Pfister K, Hackl C, Schnitzbauer AA, Stroszczynski C, Schlitt HJ, Geissler EK, Jung EM
Contrast-enhance ultrasound (CEUS) detects effects of vascular disrupting therapy in an experimental model of gastric cancer
Clin Hemorheol Microcirc. 2014;56(4):287-99.

Lang SA, Loss M, Schlitt HJ
„In-situ Split“ (ISS) – Leberresektion
Neue Aspekte zu Technik und Indikation
Zentralbl Chir. 2014 Apr;139(2):212-9.

Mycielska ME, Wachsmuth C, Dettmer K, Wagner C, Schlitt HJ, Oefner PJ, Geissler EK, **Lang SA**
Hsp90 regulates glycolysis through Tom40
J Cell Biol Cell Metab 2014; 1(1) 1-7

Fendrich V, Wichmann S, Wiese D, Waldmann J, Lauth M, Rexin P, Lopez-Lopez C, Schlitt HJ, Bartsch DK, **Lang SA**

Inhibition of Heat shock protein 90 (HSP90) with AUY922 represses tumor growth and prolongs survival in a transgenic mouse model of islet cell neoplasms
Neuroendocrinology. 2014;100(4):300-9.

Lang SA, Loss M, Wohlgemuth WA, Schlitt, HJ

Clinical management of acute portal/mesenteric vein thrombosis
Viszeralmedizin 2014 Dec 3;30(6):394-400

Brandes F, Schmidt K, Wagner C, Redekopf J, Schlitt HJ, Geissler EK, **Lang SA**

Targeting cMET with INC280 impairs tumor growth and improves efficacy of gemcitabine in pancreatic cancer
BMC Cancer. 2015 Feb 19;15(1):71.

Scheller T, Hellerbrand C, Moser C, Schmidt K, Kroemer A, Brunner SM, Schlitt HJ, Geissler EK, **Lang SA**

Improving the efficacy of targeting fibroblast growth factor receptor (FGFR) in hepatocellular carcinoma (HCC)
Br J Cancer. 2015 Mar 3;112(5):841-50.

Lang SA, Loss M, Benseler V, Glockzin G, Schlitt HJ

Long-term results after in-situ split (ISS) liver resection
Langenbecks Arch Surg. 2015 Apr;400(3):361-9.

Schmidt K, Moser C, Hellerbrand C, Zieker D, Wagner C, Redekopf J, Schlitt HJ, Geissler EK, **Lang SA**

Targeting fibroblast growth factor receptor (FGFR) with BGJ398 in a gastric cancer model
Anticancer Res. 2015 Dec;35(12):6655-65.

Hackl C, Schlitt HJ, Renner P, **Lang SA.**

Liver surgery in cirrhosis and portal hypertension.
World J Gastroenterol. 2016 Mar 7;22(9):2725-35. Review.

Koautorenschaften

Gerdes B, Ramaswamy A, Kersting M, Ernst M, **Lang S**, Schuermann M, Wild A, Bartsch DK

p16(INK4a) alterations in chronic pancreatitis – indicator for high-risk lesions for pancreatic cancer.

Surgery 2001 Apr;129(4):490-7

Gerdes B, Ramaswamy A, Ziegler A, **Lang SA**, Kersting M, Baumann R, Wild A, Moll R, Rothmund M, Bartsch DK

p16INK4a is a prognostic marker in resected ductal pancreatic cancer: an analysis of p16INK4a, p53, MDM2 and Rb.

Ann of Surg 2002 Jan;235(1):51-9

Bartsch DK, Sina-Frey M, **Lang S**, Wild A, Gerdes B, Barth P, Kress P, Grutzmann R, Colombo-Benkmann M, Ziegler A, Hahn SA, Rothmund M, Rieder H

CDKN2A germline mutations in familial pancreatic cancer.

Ann of Surg 2002 Dec;236(6):730-7

Popp FC, Eggert N, Hoy L, **Lang SA**, Obed A, Piso P, Schlitt HJ, Dahlke MH

Who is willing to take the risk? Assessing the readiness for living liver donation in the general German population.

J Med Ethics 2006 Jul;32(7):389-394

Popp FC, Slowik P, Eggenhofer E, Renner P, **Lang SA**, Stoeltzing O, Geissler EK, Piso P, Schlitt HJ, Dahlke MH

No contribution of multipotent mesenchymal stromal cells to liver regeneration in a rat model of prolonged hepatic injury.

Stem Cells. 2007 Mar;25(3):639-45.

Jaeger MD, Liu JY, Timrott KF, Popp FC, Stoeltzing O, **Lang SA**, Piso P, Geissler EK, Schlitt HJ, Dahlke MH

Sirolimus promotes tolerance for donor and recipient antigens after MHC class II disparate bone marrow transplantation in rats.

Exp Hematol. 2007 Jan;35(1):164-70.

Koehl GE, Wagner F, Stoeltzing O, **Lang SA**, Steinbauer M, Schlitt HJ, Geissler EK
Mycophenolate mofetil inhibits tumor growth and angiogenesis in vitro but has variable antitumor effects in vivo, possibly related to bioavailability

Transplantation, 2007 Mar 15;83(5):607-14

Piso P, Dahlke MH, Ghali N, Iesalnieks I, Loss M, Popp F, von Breitenbuch P, Agha A, **Lang SA**, Kullmann F, Schlitt HJ

Multimodality treatment of peritoneal carcinomatosis from colorectal cancer: first results of a new German center for peritoneal surface malignancies.

Int J Colorectal Dis. 2007 Nov;22(11):1295-300.

Moser C, **Lang SA**, Stoeltzing O

The direct effects of anti-vascular endothelial growth factor therapy on tumor cells

Clin Colorectal Cancer, 2007 Jul;6(8):564-71

Glockzin G, Ghali N, **Lang SA**, Schlitt HJ, Piso P
Peritoneal carcinomatosis : Surgical treatment, including hyperthermal intraperitoneal chemotherapy.
Chirurg. 2007 Dec;78(12):1100-1110

Moser C, **Lang SA**, Kainz S, Gaumann A, Fichtner-Feigl S, Koehl GE, Schlitt HJ, Geissler EK, Stoeltzing O
Blocking Hsp90 inhibits invasive properties and hepatic growth of human colon cancer cells and improves efficacy of oxaliplatin in p53-deficient colon cancer tumors *in vivo*
Mol Can Ther, 2007 Nov;6(11):2868-78

Piso P, Ghali N, Dahlke MH, Popp FC, **Lang SA**, Glockzin G, von Breitenbuch P, Agha A, Schlitt HJ, Ortmann O
Intraoperative Hyperthermic Intraperitoneal Chemotherapy as a Therapeutic Option for Ovarian Carcinoma – Recent Developments
Geburtsh Frauenheilk, 2007; 67: 1317-1323

Moser C, Schachtschneider P, **Lang SA**, Gaumann A, Mori A, Zimmermann J, Schlitt HJ, Geissler EK, Stoeltzing O.
Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis.
Eur J Cancer. 2008 Jul;44(11):1577-86.

Dahlke MH, Asshoff L, Popp FC, Feuerbach S, **Lang SA**, Renner P, Slowik P, Stoeltzing O, Schlitt HJ, Piso P.
Mesenteric Ischemia - Outcome after Surgical Therapy in 83 Patients.
Dig Surg. 2008 Jun 23;25(3):213-219.

Popp FC, Eggenhofer E, Renner P, Slowik P, **Lang SA**, Kaspar H, Geissler EK, Piso P, Schlitt HJ, Dahlke MH.
Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate.
Transpl. Immunol. 2008 Nov;20(1-2):55-60.

Moser C, **Lang SA**, Stoeltzing O
Heat shock protein 90 (HSP90) as a molecular target for therapy of gastrointestinal cancers
Anticancer Res. 2009 Jun;29(6):2031-42

Mori A, Moser C, **Lang SA**, Hackl C, Gottfried E, Kreutz M, Schlitt HJ, Geissler EK, Stoeltzing O
Up-regulation of Krüppel-like factor 5 (KLF5) expression in human pancreatic cancer involves p38, HIF-1 α and cell contact, and is independent of KRAS/Raf/MEK/Erk signalling.
Mol. Cancer Res. 2009 Aug;7(8):1390-8

- Glockzin G, Ghali N, **Lang SA**, Schlitt HJ, Piso P
Results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer
J Surg Oncol. 2009 Sep 15;100(4):306-10
- Hackl C, Mori A, Moser C, **Lang SA**, Dayoub R, Weiss TS, Schlitt HJ, Geissler EK, Hellerbrand C, Stoeltzing O.
Effect of heat-shock protein-90 (HSP90) inhibition on human hepatocytes and on liver regeneration in experimental models.
Surgery. 2010 May;147(5):704-12.
- Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heat-shock protein 90 (Hsp90) inhibition.
Hackl C, **Lang SA**, Moser C, Mori A, Fichtner-Feigl S, Hellerbrand C, Dietmeier W, Schlitt HJ, Geissler EK, Stoeltzing O.
BMC Cancer. 2010 Dec 3;10(1):668.
- Schlingensiepen KH, Jaschinski F, **Lang SA**, Moser C, Geissler E, Schlitt H, Kielmanowicz M, Schneider A
TGF- β 2 Gene Silencing with Trabedersen (AP 12009) in Pancreatic Cancer.
Cancer Sci. 2011 Mar 2; epub head of print
- Schiechl G, Bauer B, Fuss I, **Lang SA**, Moser C, Ruemmele P, Rose-John S, Neurath MF, Geissler EK, Schlitt HJ, Strober W, Fichtner-Feigl S.
Tumor development in murine ulcerative colitis depends on MyD88 signaling of colonic F4/80+CD11b^{high}Gr1^{low} macrophages.
J Clin Invest. 2011 May 2;121(5):1692-708
- Moser C, **Lang SA**, Hackl C, Zhang H, Lundgren K, Hong V, McKenzie A, Weber B, Park JS, Schlitt HJ, Geissler EK, Jung YD, Stoeltzing O
Oncogenic MST1R Activity in Pancreatic and Gastric Cancer Represents a Valid Target of HSP90 Inhibitors.
Anticancer Res. 2012 Feb;32(2):427-37.
- Moser C, **Lang SA**, Hackl C, Wagner C, Scheiffert E, Schlitt HJ, Geissler EK, Stoeltzing O
Targeting HSP90 by the Novel Inhibitor NVP-AUY922 Reduces Growth and Angiogenesis of Pancreatic Cancer
Anticancer Res. 2012 Jul;32(7):2551-61.
- Schnitzbauer AA, **Lang SA**, Lang H, Schlitt HJ
ALPPS: Response to Letter to the Editor.
In-situ-split" procedure for two-staged liver resection
Ann Surg. 2012 Sep;256(3):e16-7

Schleder S, Poschenrieder F, **Lang S**, Schreyer AG.

Eine seltene aber schwerwiegende radiologische Blickdiagnose – die emphysematöse Pyelonephritis

Rofo. 2013 Feb;185(2):171-3. German. No abstract available.

Goessmann H, **Lang SA**, Fichtner-Feigl S, Scherer MN, Schlitt HJ, Stroszczynski C, Schreyer AG, Schnitzbauer AA.

Biliodigestive anastomosis: Indications, complications and interdisciplinary management.

Chirurg. 2012 Dec;83(12):1097-108.

Park JS, Khoi PN, Joo YE, Lee YH, **Lang SA**, Stoeltzing O, Jung YD.

EGCG inhibits recepteur d'origine nantais expression by suppressing Egr-1 in gastric cancer cells.

Int J Oncol. 2013 Mar;42(3):1120-6.

Glockzin G, Rochon J, Arnold D, **Lang SA**, Klebl F, Zeman F, Koller M, Schlitt HJ, Piso P.

A prospective multicenter phase II study evaluating multimodality treatment of patients with

peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial. COMBATAC study protocol.

BMC Cancer. 2013 Feb 7;13:67.

Schnitzbauer AA, **Lang SA**, Lang H, Schlitt HJ.

Reply to Letter: "The ALPPS Procedure for Extended Indications in Liver Surgery: An Old Finding Applied in Surgical Oncology".

Ann Surg. 2013 Jun;257(6):e27.

Eggenhofer E, Groell A, Ruemmele P, Scherer MN, Dahlke MH, Farkas SA, Loss M, Rovira J, Sabet-Baktach M, Koehl GE, **Lang SA**, Melter M, Schlitt HJ, Geissler EK, Kroemer A

Unconventional ROR γ t⁺ T cells drive hepatic ischemia reperfusion injury

J Immunol. 2013 Jun 5. [Epub ahead of print]

Gottfried E, **Lang SA**, Renner K, Bosserhoff A, Gronwald W, Rehli M, Einhell S, Gedig I, Singer K, Seilbeck A, Mackensen A, Grauer O, Hau P, Dettmer K, Andreesen R, Oefner PJ, Kreutz M

New Aspects of an Old Drug - Diclofenac Targets MYC and Glucose Metabolism in Tumor Cells

PLoS One. 2013 Jul 9;8(7):e66987

Malaisé M, Rovira J, Renner P, Eggenhofer E, Sabet-Baktach M, Lantow M, **Lang SA**, Koehl GE, Farkas SA, Loss M, Agha A, Campistol JM, Schlitt HJ, Geissler EK, Kroemer A.

KLRG1⁺ NK Cells Protect T-bet-Deficient Mice from Pulmonary Metastatic Colorectal Carcinoma.

J Immunol. 2014 Feb 15;192(4):1954-61.

Loss M, **Lang SA**, Uller W, Wohlgemuth WA, Schlitt HJ.
Combined Surgical and Interventional Therapy of Acute Portal Vein Thrombosis without Cirrhosis: A New Effective Hybrid Approach for Recanalization of the Portal Venous System.

J Am Coll Surg. 2014 Mar;218(3):e79-86.

Wachsmuth CJ, Dettmer K, **Lang SA**, Mycielska ME, Oefner PJ
Continuous water infusion enhances atmospheric pressure chemical ionization of methyl chloroformate derivatives in gas chromatography coupled to time-of-flight mass spectrometry based metabolomics

Anal Chem. 2014 Sep 16;86(18):9186-95.

Glockzin G, Gerken M, **Lang SA**, Klinkhammer-Schalke M, Piso P, Schlitt HJ
Oxaliplatin-based versus irinotecan-based hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colorectal peritoneal metastasis: a retrospective analysis

BMC Cancer. 2014 Nov 4;14:807.

Gaumann A, Drexler H, **Lang SA**, Stoeltzing O, Diermeier-Daucher S, Buchdunger E, Wood J, Bold G, Breier G

The inhibition of tyrosine kinase receptor signaling in leiomyosarcomas cells using the small molecule kinase inhibitor PTK787/ZK222584 (Vatalanib®)

Int J Oncol. 2014 Dec;45(6):2267-77.

Verloh N, Haimerl M, Zeman F, Teufel A, **Lang S**, Stroszczyński C, Fellner C, Wiggermann P

Multivariable analysis of clinical influence factors on liver enhancement of Gd-EOB-DTPA enhanced 3T MRI

Rofo. 2015 Jan;187(1):29-35.

Dollinger M, Müller-Wille R, Beyer L, Niessen C, Teufel A, **Lang SA**, Stroszczyński C, Wiggermann P

Irreversible electroporation of malignant hepatic tumors - Alterations in hepatic and portal veins at subacute follow-up and evolution at mid-term follow-up

PLoS One. 2015 Aug 13;10(8)

Koch A, **Lang SA**, Wild PJ, Berneburg M, Bosserhoff AK, Hellerbrand C

GLUT1 expression induces metastasis of malignant melanoma cells

Oncotarget. 2015 Oct 20;6(32):32748-60.

Dollinger M, Zeman F, Niessen C, **Lang SA**, Beyer LP, Müller M, Stroszczyński C, Wiggermann P

Bile Duct Injury after Irreversible Electroporation of Hepatic Malignancies: Evaluation of MR Imaging Findings and Laboratory Values.

J Vasc Interv Radiol. 2016 Jan;27(1):96-103.

Renner P, Schuhbaum J, Kroemer A, Zeman F, Loss M, **Lang SA**, Geissler EK, Schlitt HJ, Farkas SA

Morbidity of hepatic resection for intermediate and advanced hepatocellular carcinoma.

Langenbecks Arch Surg. 2016 Feb;401(1):43-53.

Gaumann AKA, Alfer J, **Lang SA**, Geissler EK, Breier G
Receptor tyrosine kinase inhibitors: Are they Real Tumor Killer?
Int J Cancer. 2016 Feb 1;138(3):540-54. Review

Rovira J, Renner P, Sabet-Baktach M, Eggenhofer E, Koehl GE, Lantow M, **Lang SA**, Schlitt HJ, Campistol JM, Geissler EK, Kroemer A
Cyclosporine A Inhibits the T-bet Dependent anti-Tumor Response of CD8+ T cells
Am J Transplant. 2016 Apr;16(4):1139-47.

Buchbeiträge

Lang SA, Stoeltzing O, Klein D, Bolder U, Schlitt HJ, Geissler EK
Inhibition von mTOR reduziert Tumorwachstum und Angiogenese des Magenkarzinoms in einem experimentellen Modell
Deutsche Gesellschaft für Chirurgie; Chirurgisches Forum; Springer Verlag; S:113-4, 2005

Lang SA, Schlitt HJ, Geissler EK, Stoeltzing O
Die Angiogenese in der onkologischen Forschung – Perspektiven für die Chirurgie
Chirurgische Forschung.
Krukemeyer M.G., Spiegel H.-U. (Herausg.), Münster: Thieme Verlag, 5:291-303, 2006

Stoeltzing O, **Lang SA**, Klein D, Bolder U, Schlitt HJ, Geissler EK
Blockade von Hsp90 hemmt den EGFR/HER-2/HIF-1 α /STAT3 Signalweg in humanen Magenkarzinomzellen *in vitro* und reduziert Tumorwachstum und Angiogenese in einem experimentellen Modell *in vivo*
Deutsche Gesellschaft für Chirurgie; Chirurgisches Forum; Springer Verlag; S:45-47, 2006

Lang SA, Stoeltzing O, Dahlke MH, Piso P, Schlitt HJ
Zunahme der Anzahl behandelter Lebertumore in Ostbayern führt zu neuen Herausforderungen – ein Update für kolorektale Lebermetastasen
TUZ Journal Regensburg, 2006

Lang SA, Stoeltzing O
Tumor models: analysis of angiogenesis *in vivo*
Angiogenesis assays: A Critical Appraisal of Current Techniques
Staton, Carolyn / Lewis, Claire / Bicknell, Roy (Hrsg.), John Wiley & Sons, 2006

Schachtschneider P, **Lang SA**, Moser C, Zülke C, Kaufmann B, Schlitt HJ, Geissler EK, Stöltzing O
Kombinierte Inhibition von Raf-Kinase und IGF-IR blockiert multiple pro-angiogenetische Signalwege und steigert die Chemosensitivität humaner Pankreaskarzinomzellen
Deutsche Gesellschaft für Chirurgie; Chirurgisches Forum; Springer Verlag; 2007

Lang SA, Moser C, Dahlke MH, Popp FC, Schlitt HJ, Piso P, Geissler EK, Stöltzing O
Blockade von Hsp90 inhibiert multiple pro-angiogenetische Signalwege *in vitro* und vermindert Angiogenese und Tumorwachstum humaner Pankreaskarzinomzellen *in vivo*
Deutsche Gesellschaft für Chirurgie; Chirurgisches Forum; Springer Verlag; 2007

Moser, **Lang SA**, Zhang H, Burrows F, Bolder U, Schlitt HJ, Geissler EK, Stöltzing O

Inhibition von Heat-shock Protein 90 (Hsp90) mittels EC154, einem neuen synthetischen Hsp90 Antagonist, reduziert das Wachstum von humanen Magen- und Pankreaskarzinomzellen *in vivo*

Deutsche Gesellschaft für Chirurgie; Chirurgisches Forum; Springer Verlag; 2008

Lang SA, Moser C, Brecht I, Kaufmann B, Obed A, Schlitt HJ, Geissler EK, Stöltzing O

Duale Inhibition von Raf-B und VEGFR2 reduziert Vaskularisierung und Wachstum des hepatozellulären Karzinoms

Deutsche Gesellschaft für Chirurgie; Chirurgisches Forum; Springer Verlag; 2008

Lang SA, Moser C, Hackl C, Schenk C, Schlitt HJ, Stöltzing O, Geissler EK

STAT5b als neues „Target“ für anti-neoplastische Therapiekonzepte beim humanen Pankreaskarzinom

Deutsche Gesellschaft für Chirurgie; Chirurgisches Forum; Springer Verlag; 2010

Glockzin G, Rochon J, Arnold D, **Lang SA**, Klebl F, Koller M, Schlitt HJ, Piso P

Additive Therapieoptionen bei ausgewählten Patienten mit peritoneal metastasiertem Kolon- und Appendixkarzinom

Journal Onkologie, 2010; 08:412-414

Lang SA, Moser C, Schnitzbauer AA, Schlitt HJ

Contra: Radiochemotherapie beim Pankreaskarzinom

Journal Onkologie, 2011; 02: 72-76